SLC5A2 and type 2 diabetes mellitus: Three landmark trials, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME), Canagliflozin Cardiovascular Assessment Study (CANVAS) and Dapagliflozin Effect on Cardiovascular Events (DECLARE-RTIM58), demonstrated the beneficial effects of SGLT-2 inhibitors in preventing macrovascular events and hospitalization for HF [16].